An Economic Analysis of Erlotinib, Docetaxel, Pemetrexed and Best Supportive Care as Second or Third Line Treatment of Non-Small Cell Lung Cancer
AuthID
P-011-RD6
P-011-RD6
© 2024 CRACS & Inesc TEC - All Rights Reserved Política de Privacidade | Terms of Service